Wen-Feng Fang
Overview
Explore the profile of Wen-Feng Fang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pang L, Zhuang W, Chen Z, Liao J, Li M, Zhang L, et al.
J Natl Compr Canc Netw
. 2025 Mar;
:1-8.
PMID: 40081325
Background: Traditional chemotherapy provides restricted benefits for advanced EGFR-mutant non-small cell lung cancer (NSCLC) after failure of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), necessitating the combined treatment. However, it remains controversial which...
2.
Chen G, Sun D, Ba Y, Zhang Y, Zhou T, Zhao Y, et al.
J Hematol Oncol
. 2025 Feb;
18(1):15.
PMID: 39920751
Purpose: Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC)...
3.
Chang K, Leu S, Hu H, Chan M, Liang S, Yang K, et al.
Diagnostics (Basel)
. 2025 Jan;
15(2.
PMID: 39857042
Mechanical power (MP) refers to ventilator-delivered energy to the lungs, which may induce lung injury. We examined the relationship between MP and mortality in patients with acute respiratory distress syndrome...
4.
Pang L, Zhuang W, Li J, Li B, Huang Y, Liao J, et al.
Neoplasia
. 2024 Oct;
58:101073.
PMID: 39427513
Background: In-depth insight into the genomic features of the uncommon EGFR p.L861Q mutant NSCLC is scarcely performed, and no consensus on the preferred treatment strategy has been established. Moreover, the...
5.
Zhuang W, Hu L, Fang W
J Thorac Oncol
. 2024 Oct;
19(10):e50-e51.
PMID: 39370222
No abstract available.
6.
Tseng C, Hung K, Chang H, Huang K, Wang C, Chen Y, et al.
BMC Pulm Med
. 2024 Sep;
24(1):470.
PMID: 39333963
Purpose: This study aimed to investigate the impact of body composition variables on hospital mortality compared to other predictive factors among patients with severe pneumonia. Additionally, we aimed to monitor...
7.
Zhou H, Zhang Y, Chen G, Yu Q, Zhang H, Wu G, et al.
Signal Transduct Target Ther
. 2024 Aug;
9(1):215.
PMID: 39134529
Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study...
8.
Lin K, Fang W, Yeh J, Chiang J, Chiang H, Shao P, et al.
World J Stem Cells
. 2024 Jul;
16(6):690-707.
PMID: 38948095
Background: The treatment of acute respiratory distress syndrome (ARDS) complicated by sepsis syndrome (SS) remains challenging. Aim: To investigate whether combined adipose-derived mesenchymal-stem-cells (ADMSCs)-derived exosome (EX) and exogenous mitochondria (mito)...
9.
Hu L, Zhuang W, Chen M, Liao J, Wu D, Zhang Y, et al.
J Thorac Oncol
. 2024 Mar;
19(8):1186-1200.
PMID: 38553005
Introduction: EGFR-mutated NSCLC is characterized by an immunosuppressive microenvironment that confers limited clinical effectiveness to anti-PD-1 or PD-L1 antibodies. Despite the discouraging outcomes of immunotherapy, novel immune checkpoints are constantly...
10.
Pang L, Zhuang W, Huang Y, Liao J, Li M, Lv Y, et al.
Lung Cancer
. 2024 Mar;
190:107528.
PMID: 38461768
Introduction: The literature on de novo EGFR-mutant patients diagnosed with lung cancer is limited, and there is currently no consensus concerning the most effective treatment protocols. This study aimed to...